Cabaletta Bio (CABA) News Today $2.39 +0.05 (+2.14%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$2.38 -0.01 (-0.38%) As of 01/31/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Cabaletta Bio to Present at Guggenheim’s SMID Cap Biotech ConferenceJanuary 31 at 4:22 PM | msn.comCabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech ConferenceJanuary 29 at 11:55 AM | markets.businessinsider.comCabaletta Bio to Participate in Guggenheim's SMID Cap Biotech ConferenceJanuary 29 at 8:00 AM | globenewswire.comCabaletta Bio, Inc. (NASDAQ:CABA) Holdings Decreased by JPMorgan Chase & Co.JPMorgan Chase & Co. cut its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 70.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 279,954 shares of the company's stock after selling 676,735 sJanuary 25, 2025 | marketbeat.comCantor Fitzgerald Estimates Cabaletta Bio FY2025 EarningsJanuary 24, 2025 | americanbankingnews.comCantor Fitzgerald Comments on Cabaletta Bio FY2025 EarningsCabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Cabaletta Bio in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share of ($2.19)January 23, 2025 | marketbeat.comCabaletta Bio's (CABA) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $25.00 price objective on shares of Cabaletta Bio in a research report on Friday.January 18, 2025 | marketbeat.comCabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of "Buy" from BrokeragesShares of Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) have been given an average rating of "Buy" by the nine analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and oJanuary 18, 2025 | marketbeat.comCabaletta Bio stock maintain buy rating on trial progressJanuary 17, 2025 | msn.comCabaletta Bio: Advancing Clinical Trials and Strategic Positioning Justify Buy RatingJanuary 17, 2025 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Cabaletta Bio (NASDAQ:CABA)HC Wainwright reiterated a "buy" rating and issued a $25.00 price target on shares of Cabaletta Bio in a research report on Friday.January 17, 2025 | marketbeat.comCabaletta Bio Advances Autoimmune Therapy, Sets Strategic Goals for 2025January 17, 2025 | msn.comWilliam Blair Remains a Buy on Cabaletta Bio (CABA)January 14, 2025 | markets.businessinsider.comCabaletta Bio announces strategic priorities, anticipated milestones for 2025January 14, 2025 | markets.businessinsider.comCabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025January 13, 2025 | markets.businessinsider.comCabaletta Bio: Finding Optimism In Dire StraitsJanuary 6, 2025 | seekingalpha.comCabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Up 38.2% in DecemberCabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 6,220,000 shares, a growth of 38.2% from the November 30th total of 4,500,000 shares. Based on an average daily volume of 2,280,000 shares, the days-to-cover ratio is currently 2.7 days.December 30, 2024 | marketbeat.comState Street Corp Sells 1,109,678 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA)State Street Corp trimmed its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 55.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 896,123 shares of the company's stock after selling 1,109,678December 30, 2024 | marketbeat.comWuXi AppTec enters into a deal to sell Navy Yard operations of WuXi Advanced TherapiesDecember 24, 2024 | bizjournals.comCabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Rating of "Buy" from AnalystsCabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) has been assigned a consensus rating of "Buy" from the nine research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has given aDecember 24, 2024 | marketbeat.comEvercore ISI Group Downgrades Cabaletta Bio (CABA)December 20, 2024 | msn.comCabaletta Bio downgraded at Evercore ISI on lack of financing clarityDecember 20, 2024 | markets.businessinsider.comWells Fargo Downgrades Cabaletta Bio (CABA)December 20, 2024 | msn.comCabaletta Bio downgraded to Equal Weight from Overweight at Wells FargoDecember 20, 2024 | markets.businessinsider.comCabaletta Bio (NASDAQ:CABA) Lowered to "Inline" Rating by Evercore ISIEvercore ISI downgraded shares of Cabaletta Bio from an "outperform" rating to an "inline" rating and cut their target price for the company from $15.00 to $6.00 in a research note on Friday.December 20, 2024 | marketbeat.comCabaletta Bio (NASDAQ:CABA) Downgraded by Wells Fargo & Company to Equal WeightWells Fargo & Company cut Cabaletta Bio from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $12.00 to $6.00 in a research report on Thursday.December 19, 2024 | marketbeat.comCabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measuresDecember 10, 2024 | finance.yahoo.comPoint72 Asset Management L.P. Makes New $3.15 Million Investment in Cabaletta Bio, Inc. (NASDAQ:CABA)Point72 Asset Management L.P. acquired a new position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 667,275 shares of the company's stock, valued at approxDecember 10, 2024 | marketbeat.comCabaletta Bio, Inc. (NASDAQ:CABA) Shares Bought by Walleye Capital LLCWalleye Capital LLC boosted its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 111.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 401,982 shares of the company's stock after buDecember 5, 2024 | marketbeat.comStock Traders Purchase High Volume of Call Options on Cabaletta Bio (NASDAQ:CABA)Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) was the target of some unusual options trading on Friday. Traders bought 3,715 call options on the company. This represents an increase of 1,730% compared to the typical volume of 203 call options.November 29, 2024 | marketbeat.comCabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Rating of "Buy" by AnalystsShares of Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) have been assigned an average rating of "Buy" from the ten brokerages that are currently covering the stock, MarketBeat Ratings reports. Ten research analysts have rated the stock with a buy rating. The average 12 month target price amoNovember 29, 2024 | marketbeat.comCabaletta Bio Presents Positive Data On CABA-201 At ACR Convergence 2024November 28, 2024 | nasdaq.comCabaletta Bio to Participate in Upcoming Investor Conferences in DecemberNovember 26, 2024 | markets.businessinsider.comCabaletta Bio Unveils Promising Data on CABA-201 at ACR Convergence 2024November 22, 2024 | msn.comCabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024November 20, 2024 | nasdaq.comCabaletta Bio Reports Q3 2024 Financial ResultsNovember 19, 2024 | markets.businessinsider.comCabaletta Bio Reveals CABA-201's Positive Clinical Safety And Efficacy DataNovember 18, 2024 | markets.businessinsider.comCabaletta Bio announces updated clinical data on CABA-201November 18, 2024 | markets.businessinsider.comCabaletta Bio’s Promising Expansion and Strategic Positioning Earns Buy RatingNovember 16, 2024 | markets.businessinsider.comCabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial AdvancementsNovember 16, 2024 | msn.comCabaletta Bio’s Promising Trial Results and Proactive Management Secure Buy RatingNovember 15, 2024 | markets.businessinsider.comCabaletta Bio (NASDAQ:CABA) Given New $12.00 Price Target at Wells Fargo & CompanyWells Fargo & Company dropped their price target on shares of Cabaletta Bio from $20.00 to $12.00 and set an "overweight" rating on the stock in a research note on Friday.November 15, 2024 | marketbeat.comCabaletta Bio (NASDAQ:CABA) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $25.00 target price on shares of Cabaletta Bio in a research note on Friday.November 15, 2024 | marketbeat.comCabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 14, 2024 | markets.businessinsider.comCabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim’s Healthcare Innovation Conference!November 8, 2024 | msn.comCabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation ConferenceNovember 6, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Cabaletta Bio (CABA)November 6, 2024 | markets.businessinsider.comCabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by AnalystsShares of Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) have been given a consensus rating of "Buy" by the ten analysts that are covering the firm, Marketbeat Ratings reports. Ten research analysts have rated the stock with a buy recommendation. The average 1-year target price among analystsNovember 4, 2024 | marketbeat.comWe're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn RateOctober 30, 2024 | finance.yahoo.comCabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Down 28.9% in OctoberCabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) was the target of a large decline in short interest in October. As of October 15th, there was short interest totalling 3,780,000 shares, a decline of 28.9% from the September 30th total of 5,320,000 shares. Based on an average daily trading volume, of 1,040,000 shares, the short-interest ratio is presently 3.6 days.October 28, 2024 | marketbeat.com Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address CABA Media Mentions By Week CABA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CABA News Sentiment▼0.800.69▲Average Medical News Sentiment CABA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CABA Articles This Week▼43▲CABA Articles Average Week Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PROK News Today KROS News Today ORGO News Today GHRS News Today SIGA News Today SAGE News Today ARCT News Today MREO News Today TRML News Today PHAT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CABA) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
